Bremelanotide Recruiting Phase 4 Trials for Hypoactive Sexual Desire Disorder (HSDD) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT04179734Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire Disorder